The use of CRISPR-induced base editing of CAR T-cells has since been used in clinical trials, including a Phase I study of pediatric T-ALL patients treated with off-the-shelf anti-CD7 CAR-T with inactivated CD52, CD7, and β chain of the αβ T-cell receptor to evade lymphodepleting serotherapy, fratricide, and graft-versus-host disease, respectively [66]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.